Studio Interview with Ian Lewis, Founder & CEO of Rapid Infection Diagnostics Inc. (RID) at LSI USA ’25

In March 2025, RID’s CEO, Dr. Ian Lewis, sat down for a studio interview at the LSI USA ‘25 Emerging Medtech Summit in Dana Point, California, to share how Rapid Infection Diagnostics Inc. is rethinking the status quo in infectious disease testing.

Hosted by Life Science Intelligence (LSI), LSI USA brings together over 1,500 Medtech leaders, including 370+ innovators, 350+ investors and strategics, and top minds across the healthcare innovation ecosystem. One of the standout features of the event is the LSI Studio, where key voices in the industry join live, on-site interviews to discuss the technologies shaping the future of healthcare.

In his conversation, Dr. Lewis explains how RID’s platform bypasses outdated culture-based methods and instead uses mass spectrometry and metabolomics to rapidly identify pathogens and determine antibiotic susceptibility, all in a format designed for high-throughput, consolidated labs. He highlights the clinical urgency driving this innovation, the unmet needs of large lab networks, and the progress RID is making toward commercialization, with Alpha testing now live at one of Canada’s largest reference labs and early adoption already underway.

He also speaks about the real human impact of this work: reducing diagnostic delays that put lives at risk and enabling frontline clinicians to make confident treatment decisions, fast.

🎥 You can watch the full interview here.